ELF3, which is predicted to drive the expression of highly expressed ID genes ANXA3, TGFB2, and duct marker KRT8, has been shown to drive ligand-independent transactivation of CTNNB1 in cancer models (113, 114). The gene discussed is TGFB2; the disease is cancer.